EA201690978A1 - ПИРРОЛО[1.2-f][1.2.4]ТРИАЗИНЫ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫХ ВИРУСНЫХ ИНФЕКЦИЙ - Google Patents

ПИРРОЛО[1.2-f][1.2.4]ТРИАЗИНЫ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫХ ВИРУСНЫХ ИНФЕКЦИЙ

Info

Publication number
EA201690978A1
EA201690978A1 EA201690978A EA201690978A EA201690978A1 EA 201690978 A1 EA201690978 A1 EA 201690978A1 EA 201690978 A EA201690978 A EA 201690978A EA 201690978 A EA201690978 A EA 201690978A EA 201690978 A1 EA201690978 A1 EA 201690978A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
pirrolo
respiratory
viral infections
triazines used
Prior art date
Application number
EA201690978A
Other languages
English (en)
Other versions
EA029712B1 (ru
Inventor
Майкл О'Нил Хенрехен Кларк
Эдвард Доуэрффлер
Ричард Л. Макман
Дастин Сиджел
Original Assignee
Гайлид Сайэнсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690978(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Гайлид Сайэнсиз, Инк. filed Critical Гайлид Сайэнсиз, Инк.
Publication of EA201690978A1 publication Critical patent/EA201690978A1/ru
Publication of EA029712B1 publication Critical patent/EA029712B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

В настоящем документе предложены композиции, способы применения и соединения замещенных тетрагидрофуранилпирроло[1.2-f][1.2.4]триазин-4-аминов формулы (I) для лечения инфекции вирусом Pneumovirinaes, включая респираторно-синцитиальные вирусные инфекции, а также способы и промежуточные соединения для синтеза соединений тетрагидрофуранилпирроло[1.2-f][1.2.4]триазин-4-амина.
EA201690978A 2013-11-11 2014-11-06 ПИРРОЛО[1.2-f][1.2.4]ТРИАЗИНЫ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫХ ВИРУСНЫХ ИНФЕКЦИЙ EA029712B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11
PCT/US2014/064412 WO2015069939A1 (en) 2013-11-11 2014-11-06 Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections

Publications (2)

Publication Number Publication Date
EA201690978A1 true EA201690978A1 (ru) 2016-09-30
EA029712B1 EA029712B1 (ru) 2018-05-31

Family

ID=52003049

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201792639A EA039734B1 (ru) 2013-11-11 2014-11-06 Пирроло[1.2-f][1.2.4]триазины, используемые для лечения респираторно-синцитиальных вирусных инфекций
EA201690978A EA029712B1 (ru) 2013-11-11 2014-11-06 ПИРРОЛО[1.2-f][1.2.4]ТРИАЗИНЫ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫХ ВИРУСНЫХ ИНФЕКЦИЙ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201792639A EA039734B1 (ru) 2013-11-11 2014-11-06 Пирроло[1.2-f][1.2.4]триазины, используемые для лечения респираторно-синцитиальных вирусных инфекций

Country Status (36)

Country Link
US (4) US9388208B2 (ru)
EP (3) EP4122932A1 (ru)
JP (7) JP6234571B2 (ru)
KR (4) KR102243724B1 (ru)
CN (3) CN110003215B (ru)
AP (1) AP2016009186A0 (ru)
AU (5) AU2014346665A1 (ru)
BR (1) BR112016010261B1 (ru)
CA (1) CA2928674C (ru)
CL (1) CL2016001120A1 (ru)
CR (1) CR20160220A (ru)
CU (1) CU20160065A7 (ru)
CY (1) CY1121948T1 (ru)
DK (2) DK3505173T3 (ru)
DO (1) DOP2016000107A (ru)
EA (2) EA039734B1 (ru)
ES (2) ES2743619T3 (ru)
GT (1) GT201600086A (ru)
HR (2) HRP20220920T1 (ru)
HU (2) HUE059683T2 (ru)
IL (1) IL245324B (ru)
LT (2) LT3505173T (ru)
MD (1) MD4596C1 (ru)
MX (2) MX2016006066A (ru)
MY (2) MY182986A (ru)
NZ (1) NZ719592A (ru)
PE (1) PE20160670A1 (ru)
PH (1) PH12016500867A1 (ru)
PL (2) PL3068405T3 (ru)
PT (2) PT3505173T (ru)
SG (1) SG11201603427XA (ru)
SI (2) SI3068405T1 (ru)
TR (1) TR201910961T4 (ru)
UA (1) UA119050C2 (ru)
WO (1) WO2015069939A1 (ru)
ZA (1) ZA201603123B (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2773773C (en) 2009-09-21 2019-04-23 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
KR102573609B1 (ko) 2014-09-26 2023-08-31 리보사이언스 엘엘씨 호흡기 세포융합 바이러스 rna 복제 억제제로서의 4'-비닐 치환된 뉴클레오시드 유도체
TWI687432B (zh) * 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
LT3785717T (lt) 2015-09-16 2022-04-11 Gilead Sciences, Inc. Coronaviridae infekcijų gydymo būdai
CA2998646C (en) 2015-09-23 2021-05-18 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JP6860585B2 (ja) 2016-03-09 2021-04-14 ヤンセン バイオファーマ インク． 非環状抗ウイルス 優先出願の参照による組み込み
US10682368B2 (en) * 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
KR20200098483A (ko) 2017-09-18 2020-08-20 얀센 바이오파마, 인크. 치환된 뉴클레오시드, 뉴클레오티드 및 이들의 유사체
CN109748921B (zh) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
GB2581936B (en) 2017-12-07 2021-02-10 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (zh) * 2018-08-07 2024-03-15 中南大学 淤浆法制备黄原酸盐的方法及系统
WO2020232194A1 (en) * 2019-05-14 2020-11-19 The Regents Of The University Of Michigan Methods for glycosylation
TWI789695B (zh) 2020-01-27 2023-01-11 美商基利科學股份有限公司 治療sars cov-2感染之方法
JP7429799B2 (ja) * 2020-02-18 2024-02-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TW202245800A (zh) 2020-02-18 2022-12-01 美商基利科學股份有限公司 抗病毒化合物
TW202315607A (zh) * 2020-02-18 2023-04-16 美商基利科學股份有限公司 抗病毒化合物
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
AU2021234308C1 (en) 2020-03-12 2024-02-22 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN112778310A (zh) 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
CN115996928A (zh) 2020-06-24 2023-04-21 吉利德科学公司 1’-氰基核苷类似物及其用途
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
EP4192839A1 (en) 2020-08-06 2023-06-14 Richter Gedeon Nyrt. Remdesivir intermediates
TW202233204A (zh) 2020-08-27 2022-09-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
CN112500417B (zh) * 2020-12-31 2022-01-21 山东诚汇双达药业有限公司 一种4-氨基吡咯并[2,1-f][1,2,4]三嗪的制备方法
EP4323362A1 (en) * 2021-04-16 2024-02-21 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US20230212199A1 (en) 2021-08-18 2023-07-06 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
PE20240654A1 (es) 2021-08-20 2024-04-04 Shionogi & Co Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2023168194A1 (en) 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20230382940A1 (en) 2022-03-03 2023-11-30 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (ru) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
DE69233690T2 (de) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
CN1646141B (zh) * 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
CA2674589A1 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
ES2393038T3 (es) 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer
EP2019519B1 (en) 2007-07-25 2011-07-06 Nokia Siemens Networks Oy Method for addressing ethernet streams with a structured GPON GEM Port ID
PT2280973E (pt) 2008-04-23 2013-02-04 Gilead Sciences Inc Análogos de carba-nucleósido para tratamento antiviral
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
CA2773773C (en) 2009-09-21 2019-04-23 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
US8455451B2 (en) * 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
PE20160217A1 (es) * 2009-09-21 2016-05-18 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
BR112013001267A2 (pt) 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
SG186830A1 (en) * 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
SG188223A1 (en) * 2010-09-20 2013-04-30 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
PL2794627T3 (pl) * 2011-12-22 2019-04-30 Alios Biopharma Inc Podstawione nukleozydy, nukleotydy i ich analogi
PT2834258T (pt) * 2012-03-13 2017-04-07 Gilead Sciences Inc Análogos de carba-nucleósido 2¿- substituído para tratamento antiviral
PE20151318A1 (es) 2012-10-08 2015-10-03 Idenix Pharmaceuticals Inc Analogos de 2'-cloro nucleosido para infeccion por vhc
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
DK3505173T3 (da) 2022-08-22
KR102243724B1 (ko) 2021-04-23
AU2019204381B2 (en) 2021-04-01
EA029712B1 (ru) 2018-05-31
EA201792639A1 (ru) 2018-09-28
JP2018021051A (ja) 2018-02-08
KR102113705B1 (ko) 2020-05-21
CU20160065A7 (es) 2016-09-30
CN110003215B (zh) 2021-12-17
PT3505173T (pt) 2022-11-18
AU2017232039C1 (en) 2019-07-25
IL245324B (en) 2018-08-30
JP6393380B2 (ja) 2018-09-19
AU2019204381A1 (en) 2019-07-11
WO2015069939A1 (en) 2015-05-14
JP7247155B2 (ja) 2023-03-28
CR20160220A (es) 2016-07-22
CN114085243B (zh) 2024-04-26
DOP2016000107A (es) 2016-06-15
HRP20191303T1 (hr) 2019-10-18
MX2016006066A (es) 2016-08-12
EP3068405B1 (en) 2019-05-01
JP6234571B2 (ja) 2017-11-22
AU2021201554B2 (en) 2023-02-02
US10377761B2 (en) 2019-08-13
CN105899216A (zh) 2016-08-24
CN110003215A (zh) 2019-07-12
CN114085243A (zh) 2022-02-25
ES2743619T3 (es) 2020-02-20
ZA201603123B (en) 2019-08-28
JP2020055855A (ja) 2020-04-09
NZ719592A (en) 2017-12-22
AP2016009186A0 (en) 2016-04-30
US20190055253A1 (en) 2019-02-21
ES2926155T3 (es) 2022-10-24
KR20180059958A (ko) 2018-06-05
AU2021201554A1 (en) 2021-04-01
UA119050C2 (uk) 2019-04-25
LT3068405T (lt) 2019-08-12
CA2928674A1 (en) 2015-05-14
CN105899216B (zh) 2019-03-05
CA2928674C (en) 2018-10-02
MD4596C1 (ru) 2019-05-31
US9388208B2 (en) 2016-07-12
IL245324A0 (en) 2016-06-30
US20170008897A1 (en) 2017-01-12
SG11201603427XA (en) 2016-05-30
LT3505173T (lt) 2022-10-10
DK3068405T3 (da) 2019-07-29
JP7054394B2 (ja) 2022-04-13
KR20160074011A (ko) 2016-06-27
US20150133395A1 (en) 2015-05-14
PH12016500867A1 (en) 2016-06-20
PL3068405T3 (pl) 2019-10-31
JP2018070658A (ja) 2018-05-10
MX2020010628A (es) 2020-10-22
MD4596B1 (ru) 2018-10-31
TR201910961T4 (tr) 2019-08-21
US9701682B2 (en) 2017-07-11
SI3505173T1 (sl) 2022-09-30
AU2017232039A1 (en) 2017-10-12
EP3068405A1 (en) 2016-09-21
JP2022088661A (ja) 2022-06-14
EA039734B1 (ru) 2022-03-04
JP2017502925A (ja) 2017-01-26
US10059716B2 (en) 2018-08-28
PT3068405T (pt) 2019-08-05
CY1121948T1 (el) 2020-10-14
BR112016010261B1 (pt) 2022-02-08
MD20160063A2 (ru) 2016-11-30
KR20200057103A (ko) 2020-05-25
HRP20220920T1 (hr) 2022-10-28
KR101864973B1 (ko) 2018-06-05
GT201600086A (es) 2018-01-17
EP3505173B1 (en) 2022-07-06
EP4122932A1 (en) 2023-01-25
AU2023202506A1 (en) 2023-05-11
AU2014346665A1 (en) 2016-05-19
HUE059683T2 (hu) 2022-12-28
CL2016001120A1 (es) 2017-05-05
BR112016010261A2 (ru) 2017-08-08
PE20160670A1 (es) 2016-07-10
MY197933A (en) 2023-07-25
SI3068405T1 (sl) 2019-08-30
AU2017232039B2 (en) 2019-03-28
MY182986A (en) 2021-02-05
KR20210046833A (ko) 2021-04-28
EP3505173A1 (en) 2019-07-03
KR102355881B1 (ko) 2022-01-25
JP2024041986A (ja) 2024-03-27
PL3505173T3 (pl) 2022-10-17
US20180016280A1 (en) 2018-01-18
JP2021046413A (ja) 2021-03-25
HUE044960T2 (hu) 2019-12-30

Similar Documents

Publication Publication Date Title
EA201690978A1 (ru) ПИРРОЛО[1.2-f][1.2.4]ТРИАЗИНЫ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫХ ВИРУСНЫХ ИНФЕКЦИЙ
EA201690224A1 (ru) Противовирусные соединения
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201590197A1 (ru) Соединения для лечения парамиксовирусных вирусных инфекций
EA201791886A1 (ru) Антивирусные соединения
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201592198A1 (ru) Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
EA201792370A1 (ru) Пиразоло- и триазолопиримидиновые соединения с противовирусной активностью по отношению к rsv
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
EA201790234A1 (ru) 2'-хлораминопиримидиноновые и пиримидиндионовые нуклеозиды
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
EA201790146A1 (ru) ТИЕНО[3,2-d]ПИРИМИДИН, ФУРО[3,2-d]ПИРИМИДИН И ПИРРОЛО[3,2-d]ПИРИМИДИНЫ, ПОДХОДЯЩИЕ ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗВАННЫХ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫМ ВИРУСОМ
EA201592184A1 (ru) 4'-фтор-2'-метилзамещенные нуклеозидные производные
EA201691141A1 (ru) Соединения против ccr6
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201590892A1 (ru) Производные n-(пиридин-2-ил)пиримидин-4-амина, содержащие сульфоксиминовую группу
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201692063A1 (ru) Спиросоединения мочевины в качестве противовирусных соединений против rsv
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório

Legal Events

Date Code Title Description
TK4A Corrections in published eurasian patents